WO2016075704A2 - Compositions pharmaceutiques topiques stables contenant de la gabapentine - Google Patents

Compositions pharmaceutiques topiques stables contenant de la gabapentine Download PDF

Info

Publication number
WO2016075704A2
WO2016075704A2 PCT/IN2015/000424 IN2015000424W WO2016075704A2 WO 2016075704 A2 WO2016075704 A2 WO 2016075704A2 IN 2015000424 W IN2015000424 W IN 2015000424W WO 2016075704 A2 WO2016075704 A2 WO 2016075704A2
Authority
WO
WIPO (PCT)
Prior art keywords
gabapentin
topical pharmaceutical
pharmaceutical composition
paraffin
stable topical
Prior art date
Application number
PCT/IN2015/000424
Other languages
English (en)
Other versions
WO2016075704A3 (fr
Inventor
Amit Bakshi
Original Assignee
Eris Lifesciences Pvt Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eris Lifesciences Pvt Ltd. filed Critical Eris Lifesciences Pvt Ltd.
Publication of WO2016075704A2 publication Critical patent/WO2016075704A2/fr
Publication of WO2016075704A3 publication Critical patent/WO2016075704A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the present invention relates to stable topical pharmaceutical composition comprising gabapentin dispersed in paraffin base. More particularly, the present invention relates to stable topical pharmaceutical composition comprising micronized Gabapentin dispersed in paraffin base, optionally in combination with one or more other active ingredients , selected from at least one non-steroidal anti-inflammatory drug (NSAID) and phyto- constituents, useful in relieving neuropathic pain or neuropathy related disorders, pain related to joint and bone disorders like arthritis, osteoarthritis, rheumatoid arthritis, low back pain of varied etiology and the like.
  • NSAID non-steroidal anti-inflammatory drug
  • the invention further relates to a process for preparation of the stable topical pharmaceutical composition.
  • Neuropathy is also known as peripheral neuropathy, polyneuropathy or simply as nerve pain. It is a complication found in a number of different underlying conditions. Neuropathy means damage to nerves in the peripheral nervous system, which affects nerves outside of the brain and spinal cord.
  • PN Peripheral neuropathy
  • Common causes include systemic diseases (such as diabetes or leprosy), vitamin deficiency, medication (e.g. chemotherapy), traumatic injury, excessive alcohol consumption, immune system disease, or infection, or it may be inherited.
  • Peripheral neuropathy may be chronic or acute. Acute neuropathies demand urgent diagnosis. In acute neuropathies more than one type of nerve such as Motor nerves (that control muscles), sensory nerves or autonomic nerves are affected at the same time. Peripheral neuropathies may. be classified according to the type of nerve predominantly involved or by the underlying cause. Neuropathy may cause painful cramps, fasciculation's (fine muscle twitching), muscle loss, bone degeneration, and changes in the skin, hair and nails.
  • motor neuropathy may cause impaired balance and coordination or most commonly, muscle weakness; sensory neuropathy may cause numbness to touch and vibration, reduced position sense causing poorer coordination and balance, reduced sensitivity to temperature change and pain, spontaneous tingling or burning pain, or skin allodynia (severe pain from normally non-painful stimuli, such as light touch); and autonomic neuropathy may produce diverse symptoms, depending on the affected glands and organs, but common symptoms are poor bladder control, abnormal blood pressure or heart rate, and reduced ability to sweat normally.
  • peripheral neuropathy Many treatment strategies for peripheral neuropathy are symptomatic.
  • a range of drugs that act on the central nervous system such as drugs originally intended as antidepressants and antiepileptic drugs have been found to be useful in managing neuropathic pain.
  • Commonly used treatments include using a tricyclic antidepressant (such as amitriptyline) and antiepileptic therapies such as gabapentin or sodium valproate. These have the advantage that besides being effective in many cases, they are relatively low cost.
  • Gabapentin is a pharmaceutical drug, specifically a GAB A analog, also called an anticonvulsant. It was originally developed to treat epilepsy and currently is used to relieve neuropathic pain. It is recommended as a first line agent for the treatment of neuropathic pain arising from diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. It is used in adults to treat nerve pain caused by herpes virus or shingles (herpes zoster), restless legs syndrome (RLS) or seizures.
  • GAB A analog also called an anticonvulsant.
  • any treatment which is to be applied locally is of immense therapeutic value as the drug is directly applied to site of disorder and systemic exposure of drug is avoided, decreasing the incidence of serious side effects.
  • the pathophysiology of these disorders more or less involves different components such as over active receptors for Gabapentin, Inflammation and Nociception.
  • Gabapentin becomes chemically unstable when it is used in topical composition. It gets converted into beta-lactam under two conditions - dissolution (either in aqueous or non-aqueous medium) and exposure to higher temperature (>40°C).
  • US20110178177 discloses a topical composition for the treatment of peripheral neuropathy comprising a therapeutically effective amount of ketamine and gabapentin, wherein the composition is formulated in a pharmaceutically acceptable carrier for topical administration.
  • Lipoderm® base is admixed to act as a carrier for the active ingredients of the composition.
  • no stabilization of composition was studied in US' 177.
  • US7687080 claims a topical composition for the treatment of peripheral neuropathy comprising ketamine, gabapentin and clonidine.
  • the topical compositions of US'080 are prepared by cold compounding and stability data of composition was not provided.
  • US20060223788 describes an analgesic mixture comprising Piroxicam; Dexamethasone; Ketamine; Lidocaine injection; Dimethyl sulfoxide; Gabapentin; applied topically for the relief of pain of arthritis, neuropathy, post-herpetic (shingles) conditions, sore muscles, tendons and ligaments, and local reactions to insect bites or stings.
  • the composition preferably used Vanicream base and no stabilization of composition was studied in US'788.
  • US8663663 claims a pharmaceutical composition comprising nifedipine, pentoxifylline, ketamine hydrochloride, gabapentin, lidocaine or pharmaceutically acceptable salt thereof, and prilocaine or pharmaceutically acceptable salts thereof.
  • composition of US'080 uses Lipoderm®ActiveMax as base and was prepared by cold compounding process.
  • Ketamine in neuropathic preparations has certain drawbacks such as it produces no muscular relaxation, worsening hypotension, some irritancy and sometimes has psychotomimetic side effects.
  • Gabapentin becomes chemically unstable when it is used in topical composition as it gets converted into beta-lactam under dissolution condition or exposure to higher temperature (>40°C).
  • beta-lactam under dissolution condition or exposure to higher temperature (>40°C).
  • inventors of the present invention have come up with a unique topical composition comprising gabapentin dispersed in an inert and non-reactive paraffin ointment base that can make the composition stable, homogenize and uniformly disperse. This also avoids degradation of active under dissolution condition or higher temperature, does not promote the formation of beta-lactam, increases shelf life and makes the composition commercially viable.
  • the present invention provides a stable and effective topical pharmaceutical composition wherein Gabapentin API is micronized to very fine particle size dispersed in paraffin base which provides a better absorption and patient compliance in effective treatments of neuropathies and other neuropathic pains.
  • the present invention provides a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising micronized gabapentin dispersed in paraffin base, optionally in combination with one or more other active ingredients selected from at least one non-steroidal anti-inflammatory drug (NSAID) and phyto-constituents.
  • NSAID non-steroidal anti-inflammatory drug
  • the present invention provides a process for preparation of said stable topical composition.
  • the present invention provides topical composition comprising Gabapentin that is prepared by avoiding the two instability causing conditions viz., dissolution and exposure to elevated temperature.
  • topical composition comprising Gabapentin that is prepared by avoiding the two instability causing conditions viz., dissolution and exposure to elevated temperature.
  • various excipients were screened for suitable base under which Gabapentin is stable and during the course of screening, the inventors have found that Gabapentin is stable when it is dispersed in paraffin base.
  • the present invention describes a stable topical pharmaceutical composition comprising gabapentin dispersed in paraffin base which is effective treatments of neuropathies and other neuropathic pains.
  • the present invention provides a stable and effective topical pharmaceutical composition
  • a stable and effective topical pharmaceutical composition comprising micronized Gabapentin dispersed in paraffin base, optionally in combination with one or more other active ingredients selected from at least one non-steroidal anti-inflammatory drug (NSAID) and phyto- constituents; wherein said composition avoids degradation of active under dissolution condition or at higher temperature, does not promote the formation of beta-lactam, thereby providing better absorption and patient compliance in the treatments of neuropathies and other neuropathic pains.
  • NSAID non-steroidal anti-inflammatory drug
  • the neuropathies and other neuropathic pains or disorders includes Diabetic peripheral Neuropathy, Spondolysis, Neuropathy of other origin, Low back pain, Ankylosing Spondylitis and sciatica.
  • the micronized Gabapentin of the present invention prevents the over activity of Gabapeptin receptors. Due to micronization, better dissolution/absorption and bioavailability of the active ingredient is observed.
  • the Gabapentin used in the composition is present in an amount of 4 to 12%, preferably 8 to 12 %, more preferably 10% of the total composition.
  • the particle size of Gabapentin API ranges from 30 micron to 150 micron, preferably 90 micron.
  • paraffin base examples include Liquid Paraffin, Hard Paraffin, Light Liquid Paraffin, White soft paraffin, yellow soft paraffin and the like. These paraffin bases are used to provide a physical stability of the Gabapentin.
  • the preferred paraffin base used in the composition is white soft paraffin and is present in an amount that is sufficient to make gabapentin dispersed in the composition.
  • composition of the instant invention optionally includes other active ingredients which are added to the composition to increase its analgesic effect, absorption and/or penetration.
  • the present invention discloses a stable topical, pharmaceutical composition
  • a stable topical, pharmaceutical composition comprising micronized gabapentin dispersed in paraffin base, optionally in combination with one or more other active ingredients selected from at least one non-steroidal anti-inflammatory drug (NSAID) and phyto- constituents, useful in relieving neuropathic pain or neuropathy related disorders.
  • non-steroidal anti-inflammatory drug include Diclofenac, Ibuprofen, Dexibuprofen, Naproxen, Fenoprofen, Ketoprofen, Dexketoprofen, Flurbiprofen, Oxaprozin, Loxoprofen, or pharmaceutically acceptable salts thereof.
  • the NSAID used in the composition is preferably Ketoprofen and is present in an amount of 3 to 7%, preferably 5% of the total composition. Ketoprofen act as anti-inflammatory agent and provides analgesic effect.
  • the phyto -constituents of the present invention may be prepared synthetically by the methods known in the art and are selected from Capsaicin and Methyl Salicylate.
  • Capsaicin used in the present invention act as anti-nociceptive or analgesic and used to reduce the symptoms of peripheral neuropathy such as post-herpetic neuralgia caused by shingles.
  • the Capsaicin used in the composition is present in an amount of 0.025 to 0.075%, preferably 0.035%) of the total composition.
  • Methyl salicylate of the present invention acts as an anti-inflammatory agent.
  • the Methyl salicylate used in the composition is present in an amount of 1 to 20%, preferably 5% of the total composition.
  • the present invention provides a stable topical composition
  • a stable topical composition comprising 8 to 12% of Gabapentin; 3 to 7% of Ketoprofen; 0.025 to 0.075% of Capsaicin, 1 to 20% of Methyl salicylate and white soft paraffin (QS).
  • various topical compositions can be prepared as described below.
  • the present invention provides a stable topical composition comprising 12% > of Gabapentin; 7% of Ketoprofen; 0.075%) of Capsaicin and 20%> of Methyl salicylate and white soft paraffin (QS).
  • the present invention provides a stable topical composition comprising 10% of Gabapentin; 5%> of Ketoprofen; 0.035% of Capsaicin and 5% of Methyl salicylate and white soft paraffin (QS).
  • the present invention provides a stable topical composition comprising 8% of Gabapentin; 4% of Ketoprofen; 0.035% of Capsaicin and 1% of Methyl salicylate and white soft paraffin (QS).
  • the present invention provides a stable topical composition comprising 10% of Gabapentin and white soft paraffin (QS).
  • QS white soft paraffin
  • the stable composition of the present invention can be formulated into variety of topical dosage forms such as ointment, cream, gel, liniment, balm or lotion and the like.
  • a preferable topical composition is an ointment form.
  • the stable composition of the present invention optionally comprises other inactive excipients.
  • the present invention discloses a method of treating neuropathies and other neuropathic pains or disorders such as Diabetic peripheral Neuropathy, Spondolysis, Neuropathy of other origin, Low back pain, Ankylosing Spondylitis, sciatica, pain related to joint and bone disorders like arthritis, osteoarthritis, rheumatoid arthritis, low back pain of varied etiology and other related disorders by applying a therapeutically effective amount of the stable composition of the present invention comprising gabapentin dispersed in paraffin base, optionally in combination with one or more other active ingredients selected from at least one non-steroidal anti-inflammatory drug (NSAID) and phyto-constituents, to the affected topical area of a subject, wherein the subject is human.
  • NSAID non-steroidal anti-inflammatory drug
  • the stable composition of the present invention useful in effective treatments for neuropathies and other neuropathic pains or disorders such as Diabetic peripheral Neuropathy, Spondolysis, Neuropathy of other origin, Low back pain, Ankylosing Spondylitis, sciatica, pain related to joint and bone disorders like arthritis, osteoarthritis, rheumatoid arthritis, low back pain of varied etiology other related disorders comprising gabapentin dispersed in paraffin base, optionally in combination with one or more other active ingredients selected from at least one non-steroidal anti-inflammatory drug (NSAID) and phyto-constituents.
  • NSAID non-steroidal anti-inflammatory drug
  • the invention further discloses a process for preparation of said stable topical composition which comprises dispersing the Gabapentin in paraffin base at ambient temperature.
  • the ambient temperature according to the invention is in the range of 25°to 30°C.
  • step (d) mixing ketoprofen in mixture of step (d) followed by adding Gabapentin.
  • step (e) homogenizing the entire content of step (e) using overhead motor driven ointment homogenizer to obtain a desire product.
  • composition of the present invention was estimated for its stability at Room Temperature as well as in stability chambers with a controlled temperature and humidity conditions at 25°C/60RH, 30°C/75RH and 40°C/75RH; wherein said composition was found to be stable for around 4-5 months at RT and for 7 months at 30°C as shown in Table 2 and Table 5 respectively.
  • the instant invention provides evaluation of content uniformity of the dispersed Gabapentin. Accordingly Gabapentin dispersing in paraffin base is divided into two batches A and B and subjected to stability evaluation for 21 days as shown in Table 4, which conclusively proves that both the batches are stable and the content assay of Gabapentin indicates that the content uniformity in both the batches A and B.
  • the invention also provides permeation studies of the instant composition, wherein it has been observed that the micronized Gabapentin dispersed in paraffin base permeates very well.
  • the permeation studies were carried after the application of topical ointment on a predetermined area of SD rats. From the different groups, the skin was incised after a fixed period and also the plasma concentration was collected. Subsequently the concentration of Gabapentin in skin as well as plasma was determined using LC-MS technique.
  • the results mentioned in Example 6 - Table 6 and Table 7 clearly indicate that Gabapentin penetrates and retains in the layers of skin for up to 6 hours; whereas plasma concentration achieved is so less that levels remain below the concentrations causing adverse effects.
  • Example 2 To check the reproducibility of results obtained in Example 2, the procedure is repeated and % Gabapentin is evaluated after definite intervals for a period of 150 days. The results are shown in below Table 2: Table 2
  • Methyl salicylate is known to exist in liquid state and having studied the nature of Gabapentin in presence of any liquid compound, presence of Methyl salicylate can be postulated to augment the degradation of Gabapentin. Thus, to study the compatibility of Gabapentin and Methyl Salicylate together in same composition following experiment is carried out.
  • compositions are prepared, each containing 10% Gabapentin and 3%, 10% and 20% of Methyl Salicylate respectively dispersed in White soft paraffin.
  • Table 3 depicts that, in presence of 3%, 10% and 20% Methyl Salicylate, Gabapentin is found to be stable at the end of 23 rd day of study period. Hence, it is concluded that, though Gabapentin is known to degrade in presence of liquid state compound, it remains un-reactive and inert with Methyl Salicylate.
  • Example 5 Stability Study of Gabapentin, Ketoprofen, Methyl salicylate and Capsaicin in White Soft Paraffin ointment base in a pilot batch of 1kg in accelerated conditions at 25°C, 30°C and 40°C
  • Gabapentin is first added in white soft paraffin, followed by Ketoprofen. Since the quantity of Capsaicin is very less, it is dissolve in Methyl Salicylate and this mixture is added in White soft paraffin. The entire content is then homogenized using overhead motor driven ointment homogenizer.
  • ointment is then studied for homogenous distribution of APIs and then assessed for stability. This is done by taking ointment samples from two different points [top (Sample A) and bottom (Sample B)] and analyzing them individually.
  • Remaining ointment was then packed in unit containers each of 50gm and the containers were kept in controlled environment in stability chambers, having the following temperature and humidity - 25°C/60%RH, 30°C/75%RH, 40°C/75%RH.
  • Results The results from Table 4 indicate that ointment is properly homogenized as both the Samples A and B, sampled from different corners of the manufacturing vessel had similar % Gabapentin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique topique stable contenant de la gabapentine micronisée dispersée dans de la paraffine base, éventuellement en combinaison avec un ou plusieurs autres ingrédients actifs sélectionnés parmi au moins un médicament anti-inflammatoire non stéroïdien (AINS) et des composants végétaux, et se révélant utile pour soulager la douleur neuropathique ou les troubles neuropathiques, tels que la neuropathie diabétique périphérique, la spondylose, les neuropathies d'autres origines, la lombalgie, la spondylarthrite ankylosante, la sciatique, la douleur associée à des troubles articulaires et osseux tels que l'arthrite, l'arthrose, la polyarthrite rhumatoïde et la lombalgie d'étiologie variée. La présente invention porte également sur un procédé de préparation de ladite composition pharmaceutique topique stable.
PCT/IN2015/000424 2014-11-15 2015-11-16 Compositions pharmaceutiques topiques stables contenant de la gabapentine WO2016075704A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3602MU2014 2014-11-15
IN3602/MUM/2014 2014-11-15

Publications (2)

Publication Number Publication Date
WO2016075704A2 true WO2016075704A2 (fr) 2016-05-19
WO2016075704A3 WO2016075704A3 (fr) 2016-08-04

Family

ID=55955217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000424 WO2016075704A2 (fr) 2014-11-15 2015-11-16 Compositions pharmaceutiques topiques stables contenant de la gabapentine

Country Status (1)

Country Link
WO (1) WO2016075704A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210212930A1 (en) * 2018-05-30 2021-07-15 Eviderm Institute Ab Mild composition for use in topical treatment of skin and nail disorders caused by virus and fungus
CN115697316A (zh) * 2020-04-21 2023-02-03 东佩制药股份公司 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20041447A1 (it) * 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210212930A1 (en) * 2018-05-30 2021-07-15 Eviderm Institute Ab Mild composition for use in topical treatment of skin and nail disorders caused by virus and fungus
CN115697316A (zh) * 2020-04-21 2023-02-03 东佩制药股份公司 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途

Also Published As

Publication number Publication date
WO2016075704A3 (fr) 2016-08-04

Similar Documents

Publication Publication Date Title
US7052715B2 (en) Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
Mendlik et al. Treatment of neuropathic pain
JP5358574B2 (ja) 高濃度の局所麻酔薬調合物
Jain et al. Evaluation of efficacy of oral pregabalin in reducing postoperative pain in patients undergoing total knee arthroplasty
JP2014513094A (ja) 親油性医薬用薬剤の改良された非経口製剤ならびにそれを調製および使用するための方法
JP6695140B2 (ja) 水性カプサイシノイド配合物ならびにその製造法および使用法
Goerl et al. Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures
Scheinfeld Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents
US20150141515A1 (en) Compositions and methods for delivery of nsaid and anesthetic
Shokri et al. Adjuvant use of melatonin for relieving symptoms of painful diabetic neuropathy: results of a randomized, double-blinded, controlled trial
US20060069059A1 (en) Topical formulations for the treatment of depression with S adenosyl methionine
CA2362564A1 (fr) Antidepresseurs tricycliques topiques
CA2713199C (fr) Formulation topique
WO2016075704A2 (fr) Compositions pharmaceutiques topiques stables contenant de la gabapentine
Kanai et al. Efficacy of a metered-dose 8% lidocaine pump spray for patients with post-herpetic neuralgia
CA3019565A1 (fr) Compositions topiques contre une douleur neuropathique
BR112021014107A2 (pt) Método para tratar dor de osteoartrite por administração de resiniferatoxina
US20130324611A1 (en) Methods of using desensitizing drug products
Forst et al. Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain
Pradhan et al. Capsaicin
US9731021B2 (en) Hydrogel composition for the treatment of dermatological disorders
Kraychete et al. Topic drug therapy for neuropathic pain
US20060263439A1 (en) Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
Sukamdi et al. Evaluation of physical and chemical stability of semi-solid preparations towards beyond-use date
Chandra et al. SCOPE OF ILE (INTRAVENOUS LIPID EMULSION) AS AN ANTIDOTE IN VETERINARY CLINICAL PRACTICE.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15858379

Country of ref document: EP

Kind code of ref document: A2